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Abstract Factor Xa-induced stimulation of coronary artery
smooth muscle cells (CASMC) was investigated by analyzing
[3H]thymidine incorporation, cell proliferation, and ERK-1/2
activation. Exposure of the cells to factor Xa evoked a time-
dependent activation of ERK-1/2 with increased [3H]thymidine
incorporation and cell proliferation. The factor Xa-induced
ERK-1/2 activation was not desensitized by preincubation of
the cells with thrombin. However, ERK-1/2 activation was
markedly attenuated by prior exposure of the cells to pro-
tease-activated receptor-2 (PAR-2) activating peptide,
SLIGKV. The mitogenic e¡ect of factor Xa was signi¢cantly
reduced in the presence of anti-PAR-2 monoclonal antibody.
Several lines of experimental evidence indicate that factor Xa-
induced mitogenesis of CASMC is a cellular process mediated
by PAR-2 activation. 6 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
While percutaneous transluminal coronary angioplasty has
become an important tool for the management of coronary
artery disease, restenosis in at least 30^50% of cases remains
the major limiting factor of long-term e⁄cacy [1]. Neointimal
hyperplasia is an important mechanism of restenosis after
percutaneous transluminal coronary angioplasty [2]. Vascular
smooth muscle cell (SMC) migration and proliferation are
both necessary events that contribute to the formation of neo-
intimal plaque [3]. After arterial injury, SMC mitogenesis is
triggered by a large number of growth factors, cytokines, and
vasoregulatory molecules that participate in the pathogenic
process [4]. Furthermore, SMC provides a source of tissue
factor (TF) following arterial injury [5] and TF forms a
high-a⁄nity complex with factor VII/VIIa and thereby ini-
tiates extrinsic blood coagulation, leading to the formation
of factor Xa and thrombin [6]. It has been well established
that thrombin acts as a mitogen for SMC [7,8], as well as a
coagulant. There are several reports suggesting that the mito-
genic e¡ect of thrombin is due to the expression and release of
bFGF [9] or at least in part, PDGF [10,11]. In analogy to the
functions of thrombin, it has also been suggested that factor
Xa acts as a potent mitogen for aortic SMC [12^14] and SMC
from human saphenous vein [15]. Furthermore, it has been
con¢rmed that factor Xa stimulates the release of PDGF
from rat and human aortic SMC [13,14]. Thus, factor Xa-
stimulated mitogenic e¡ect on aortic SMC appears to be
mediated via release of PDGF from SMC, whereas factor
Xa-induced signaling and mitogenic activity in human venous
SMC are independent of PDGF [15]. However, detailed cel-
lular mechanism of factor Xa-induced SMC proliferation has
not been elucidated yet. In this work, we have demonstrated
that factor Xa-induced mitogenesis of human coronary artery
SMC undergoes via signalling pathway triggered by protease-
activated receptor-2 (PAR-2) activation.
2. Materials and methods
2.1. Materials
Human coronary artery smooth muscle cells (CASMC) and Clo-
netics SmGM0-2 BulletKit (CC-3182) were purchased from BioWhit-
taker (USA) and [3H]thymidine from NEN Life Science Products
(USA). Clonetics SmGM0-2 BulletKit (CC-3182) contains SMC basal
medium (modi¢ed MCDB 131) and some growth supplements. Hu-
man factor Xa was purchased from Haematologic Technologies
(USA) and Pefabloc Xa from PentaPharm (Switzerland). Recombi-
nant tick anticoagulant protein (TAP) was kindly gifted by Dr. Y.
Jang (Cardiovascular Research Institute, Yonsei University College of
Medicine, Seoul, Korea). NuPAGE1 4^12% Bis-Tris gel was from
Invitrogen (USA). DC protein assay reagent was purchased from
Bio-Rad (USA). Phospho-ERK-1/2 antibody from Cell Signaling
Technology (USA), peroxidase labeled goat anti-rabbit IgG from
KPL (USA), and ECL kit from Amersham Pharmacia Biotech (Swe-
den). The PAR-2 agonist peptide SLIGKV was synthesized by Pep-
tron (Korea) and monoclonal anti-PAR-2 antibody (SAM11) was
purchased from Santa Cruz Biotechnology (UK). All other reagents
were of the highest commercial purity.
2.2. Cell culture
Human CASMC were cultured in Clonetics SmGM0-2 medium
supplemented with 10% fetal bovine serum (FBS). Cultures were
maintained in a humidi¢ed atmosphere of 5% CO2 at 37‡C. All
SMC used in these studies were from passages 4^9.
2.3. [3H]Thymidine incorporation
CASMC (4U104) were seeded into a 24-well plate and incubated
for 24 h in Clonetics SmGM0-2 medium. After further incubation of
the cells in SMC basal medium (modi¢ed MCDB 131) containing
0.5% FBS for 48 h, they were treated with inhibitors or antibodies
for 30 min before stimulation. Following an additional 24-h incuba-
tion, cells were then pulsed with 2 WCi of [3H]thymidine for 8 h at
37‡C and washed twice with phosphate-bu¡ered saline (PBS). Cells
were ¢xed in methanol at 4‡C for 5 min and washed twice in 5% TCA.
The acid-insoluble material was dissolved in 0.3 M NaOH at room
temperature followed by radioactivity measurement with liquid scin-
tillation counter.
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2.4. Cell proliferation assay
CASMC (1.25U104) were plated onto 24-well culture plates and
incubated at 37‡C for 24 h. After cells were rendered quiescent in
SMC basal medium (modi¢ed MCDB 131) containing 0.5% FBS
for 48 h, they were treated for 30 min with competitive factor Xa
inhibitors. The cells were then stimulated with 50 nM factor Xa for
72 h. The medium was removed and cell number/well was counted
using a hemocytometer.
2.5. Immunoblotting
CASMC were allowed to grow to con£uence in 6-well plates and
made quiescent in SMC basal medium (modi¢ed MCDB 131) con-
taining 0.2% FBS for 48 h. After stimulation with 50 nM factor Xa, in
the presence or absence of inhibitors and antibodies for the times
indicated, cells were rinsed in ice-cold PBS and treated with lysis
bu¡er (1% Triton X-100, 0.1% L-mercaptoethanol, 1 mM EDTA,
1 mM EGTA, 50 mM Tris^HCl (pH 7.0), 1 mM PMSF) for 20 min
on ice. Cell lysates were collected into microcentrifuge tubes, vortexed,
and centrifuged at 12 000 rpm for 20 min. Protein concentration was
measured in the supernatant using a DC protein assay reagent accord-
ing to the manufacturer’s instructions and equalized for all samples.
Reduced samples (30 Wg) were subjected to SDS^PAGE (NuPAGE1
4^12% Bis-Tris gel) and then electrotransferred to nitrocellulose mem-
brane. For detection of phosphorylated ERK-1/2, membranes were
incubated with antibody directed against a phospho-speci¢c ERK-1/
2 followed by incubation with goat anti-rabbit IgG conjugated to
horseradish peroxidase. ECL detection method was employed for col-
or development.
3. Results and discussion
In this study, we have demonstrated that factor Xa induces
mitogenesis of CASMC via activation of PAR-2. It has been
well established that factor Xa promotes aortic SMC
[12,14,16] and saphenous vein SMC [15] mitogenesis. Like-
wise, stimulation of CASMC by factor Xa caused an increase
in both [3H]thymidine incorporation and cell number as com-
pared to unstimulated CASMC (Fig. 1). The factor Xa-in-
duced DNA synthesis was markedly suppressed by the com-
petitive factor Xa inhibitors such as TAP [17] and Pefabloc
Xa [18] (Fig. 1A). Similar inhibitory e¡ect on factor Xa-in-
duced cell proliferation was also obtained with these inhibi-
tors (Fig. 1B). Factor Xa inhibitors did not in£uence
[3H]thymidine incorporation and cell proliferation on their
own (data not shown). Exposure of CASMC to factor Xa
evoked a time-dependent activation of ERK-1/2 (Fig. 2A).
Maximal kinase activation was observed in 5 min after stim-
ulation of the cell, and then returned to its basal level in 40
min. The factor Xa-induced activation of ERK-1/2 was com-
pletely suppressed by concomitant treatment of CASMC with
factor Xa inhibitors (Fig. 2B). Factor Xa inhibitors did not
a¡ect the activation of ERK-1/2 on their own (data not
shown). These results are correlated to the ¢ndings of Gasic
et al. [12] who ¢rst observed that nanomolar concentrations of
factor Xa promote cultured rat aortic SMC mitogenesis. Her-
bert et al. [14] subsequently demonstrated that factor Xa in-
creased phosphoinositide turnover as a potent mitogen in hu-
man aortic SMC. Moreover, these e¡ects were markedly
reduced by DX9065a, a speci¢c competitive inhibitor of factor
Xa [19]. In SMC from human saphenous vein, the mitogenic
e¡ect of factor Xa was also signi¢cantly suppressed by factor
Xa inhibitors [15]. These results indicate that factor Xa-in-
duced mitogenic e¡ect on SMC is closely associated with
the proteolytic enzyme activity of the factor. Furthermore, it
has been shown that factor Xa exerts its mitogenic e¡ect via
stimulating the release of PDGF in human umbilical vein
endothelial cells [20] and in cultured vascular SMC of rat
Fig. 1. Factor Xa-induced mitogenesis of CASMC. Quiescent
CASMC were stimulated with 50 nM factor Xa in the presence or
absence of competitive factor Xa inhibitors, 2 WM TAP and 2 WM
Pefabloc Xa, respectively. CASMC mitogenesis was estimated by
measuring (A) [3H]thymidine incorporation into DNA, and (B)
number of cells as described in Section 2. Error bars represent the
S.E.M. (n=4).
Fig. 2. Factor Xa-induced ERK-1/2 activation in CASMC. A:
Time-dependent activation of ERK-1/2 by factor Xa. Cells were ex-
posed to 50 nM factor Xa for the indicated times. B: E¡ect of fac-
tor Xa inhibitors on factor Xa-stimulated ERK-1/2 activation. Cells
were treated with 2 WM TAP or Pefabloc Xa for 30 min before ex-
posure to 50 nM factor Xa for 10 min. Cell lysates were assayed
for the phosphorylation of ERK-1/2 (n=3; representative experi-
ment).
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[13]. Ko et al. [13] suggested that factor Xa, via its serine
protease activity, is responsible for the release of preexisting
PDGF from vascular SMC, and the PDGF in turn activates
ERK-1/2 through the receptor tyrosine kinase. There has been
no clear evidence, however, related to the speci¢c receptor
that is activated by factor Xa leading to the release of
PDGF and mitogenesis of SMC.
Assuming that the mitogenic e¡ect is evoked by the proteo-
lytic activity of factor Xa, it was possible to postulate that the
signaling events might be induced via one of the PARs which
have recently been indenti¢ed. PAR family currently consists
of four related proteins: PAR-1 [21,22], which can be acti-
vated by thrombin or trypsin [21], PAR-2 by trypsin [23] or
tryptase [24,25], PAR-3 by thrombin [26], and PAR-4 by
thrombin or trypsin [27,28]. All of the four PAR family mem-
bers are G protein-coupled receptors that are normally acti-
vated by proteolytic exposure of a new tethered ligand. There
is experimental evidence demonstrating that thrombin stimu-
lates SMC proliferation via proteolytic activation of a recep-
tor [29,30], and tryptase- or trypsin-induced mitogenesis of
SMC is mediated by the activation of PAR-2 [31^33]. In order
to investigate whether factor Xa-induced signaling event is
mediated by the activation of a PAR in CASMC, desensitiza-
tion experiments were performed as described previously [34].
When the cells were treated with thrombin, it took 40 min for
ERK-1/2 signal to return to its basal level (data not shown).
However, it was able to induce ERK-1/2 activation again by
immediately exposing the thrombin-desensitized cells to factor
Fig. 3. Desensitization of agonist-stimulated ERK-1/2 activation by
thrombin or PAR-2 agonist peptide pretreatment. A: Time-depen-
dent activation of ERK-1/2 by SLIGKV. Cells were exposed to 200
WM SLIGKV for the indicated times. B: Cells were treated with 50
nM thrombin (TH) for 40 min prior to the second exposure to 50
nM thrombin (TH) or 50 nM factor Xa (Xa) for 10 min. C: Cells
were stimulated with 200 WM SLIGKV (SL) for 40 min prior to the
second exposure to 200 WM SLIGKV, 50 nM factor Xa, or 50 nM
thrombin for 10 min. Cell lysates were then assayed for the phos-
phorylation of ERK-1/2 (n=4; representative experiment).
Fig. 4. Expression of PAR-2 in human CASMC. Cultured cells
were sonicated in PBS for 30 s and then centrifuged at 100 000Ug
for 60 min. Precipitates were solubilized in lysis bu¡er and subjected
to SDS^PAGE (50 Wg protein/lane). After transfer to nitrocellulose
membrane, it was reacted with monoclonal anti-PAR-2 antibody
(SAM11). The protein was visualized using anti-mouse IgG conju-
gated to horseradish peroxidase and ECL detection reagent (n=3;
representative experiment).
Fig. 5. PAR-2 agonist peptide-induced mitogenesis of CASMC. Qui-
escent CASMC were stimulated with the indicated concentrations of
SLIGKV in the presence or absence of anti-PAR-2 monoclonal
antibody (SAM11) (30 Wg/ml). CASMC mitogenesis was estimated
by measuring (A) [3H]thymidine incorporation into DNA, and (B)
number of cells. Error bars represent the S.E.M. (n=5).
Fig. 6. Suppression of agonist-induced ERK-1/2 activation by anti-
PAR-2 monoclonal antibody. Cells were stimulated with 50 nM fac-
tor Xa, 50 nM thrombin (TH), or 50 WM SLIGKV(SL) for 10 min
in the presence or absence of anti-PAR-2 monoclonal antibody
(SAM11) (30 Wg/ml). Cell lysates were then assayed for the phos-
phorylation of ERK-1/2 (n=4; representative experiment).
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Xa, suggesting that the factor activates a receptor distinct
from thrombin-activated ones in CASMC (Fig. 3B). Thus,
we postulated that PAR-2 could be a strong candidate as a
factor Xa-activated receptor on CASMC. Expression of PAR-
2 was then identi¢ed in CASMC by Western blot analysis
(Fig. 4). PAR-2 is expressed in many cell types including
SMC [35], endothelial cells [36], keratinocytes [37], epithelial
cells [38], ¢broblasts [39], and mast cells [40]. Cellular function
of the receptor is associated with proliferation of several cell
lines [32,39,41], activation of blood coagulation in endothelial
cell [42], SMC contraction [43], tissue repair [37], and in£am-
matory reactions [44]. PAR-2 is activated not only by trypsin
[23] or tryptase [24,25], but also by synthetic peptide SLIGKV
[45^47]. Involvement of PAR-2 in CASMC mitogenesis was
veri¢ed by performing [3H]thymidine incorporation and cell
proliferation experiments with PAR-2 agonist peptide
SLIGKV. As expected, the agonist peptide was able to induce
cell proliferation as well as DNA synthesis in CASMC (Fig.
5). It has been reported that the agonist peptide stimulates
mitogenesis in SMC [31^33]. The agonist peptide also evoked
a time-dependent activation of ERK-1/2 with a maximum
e¡ect in 5 min, and then the kinase activation returned to
its basal level in 40 min (Fig. 3A). After the ¢rst challenge
with SLIGKV for 40 min, a second exposure of the cells to
factor Xa failed to activate ERK-1/2 (Fig. 3C). These exper-
imental results provide an evidence for the involvement of
PAR-2 in factor Xa-induced cell signaling. In contrast, throm-
bin was able to elicit ERK-1/2 activation after initial exposure
of the cells to SLIGKV. Similar ¢ndings were reported in
human umbilical vein endothelial cells [48]. Factor Xa-in-
duced Ca2þ signaling response was blocked by pretreatment
of the endothelial cells with SLIGKV, whereas PAR-1-depen-
dent response was una¡ected. Enzymatic cleavage of PAR-2
in endothelial cells by factor Xa was also demonstrated by
proteolytic digestion of a synthetic peptide duplicating the
PAR-2 cleavage site [48].
To further investigate the requirement of PAR-2 for the cell
activation, CASMC were stimulated by factor Xa in the pres-
ence of anti-PAR-2 monoclonal antibody raised against ami-
no acid residues 37^50 of PAR-2 of human origin. As illus-
trated in Fig. 6, the particular monoclonal antibody was able
to e¡ectively suppress the factor Xa-induced activation of
ERK-1/2, whereas thrombin-induced activation of the kinase
remained intact. Similar inhibitory e¡ect on factor Xa-in-
duced [3H]thymidine incorporation was also obtained with
the monoclonal antibody (Fig. 7). In contrast, thrombin-acti-
vated DNA synthesis of CASMC was una¡ected in the pres-
ence of anti-PAR-2 monoclonal antibody. The speci¢city of
the anti-PAR-2 monoclonal antibody was demonstrated by
e¡ective suppression of SLIGKV-induced ERK-1/2 activation
and [3H]thymidine incorporation (Figs. 5 and 6). The mono-
clonal antibody itself did not in£uence the phosphorylation of
ERK-1/2 and [3H]thymidine incorporation (Figs. 5 and 6).
Taken together the results obtained in Figs. 3^7, it appears
to be clear that PAR-2 mediates factor Xa-induced cell signal-
ing in CASMC.
In summary, we have demonstrated with experimental evi-
dence in this communication that factor Xa promotes human
CASMC mitogenesis which is mediated by PAR-2 activation.
Further studies on factor Xa-induced signaling pathway of
CASMC will provide useful information for understanding
cellular function of factor Xa in detail which is associated
with mitogenesis.
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